# Detection of Helicobacter Species in liver cirrhosis with and without Hepatitis (C) Virus Infection

#### Thesis

## Submitted for Partial Fulfillment of the MD Degree In Clinical and Chemical Pathology

#### By

#### **Fatma Alzahraa Mohammed Hassan**

(M.B., B. Ch, Clinical and Chemical Pathology)
Faculty of Medicine - Ain Shams University

Supervised by

### Professor/ Manal Abd Elalim Abd Elsattar

Professor of Clinical and Chemical Pathology Faculty of Medicine - Ain Shams University

### Professor/ Mohamed Abd Elmaboud Mohamed

Professor of Internal Medicine Faculty of Medicine - Ain Shams University

## **Doctor/ Hala Badr El Din Ali Othman**

Assistant Professor of Clinical and Chemical Pathology Faculty of Medicine - Ain Shams University

## **Doctor/ Hala Mahmoud Hafez**

Assistant Professor of Clinical and Chemical Pathology Faculty of Medicine - Ain Shams University

> Faculty of Medicine Ain Shams University 2015

## بِسْمِ اللَّهِ الرّحَمَٰنِ الرّحيمِ

وَ عَنِيهُ اَنْ اللهِ إِهْ اللهِ الله

पूर्वे गुष्ठे कुण्ड कुण्ड कुण्ड किन्न

وَأَنْ أَعْمَلَ صَالِماً نَرْضَاهُ

रछंब् लां्फ्र्यों रहांांच्र्यावि

[جَنَالَةِ ] الصَّالَكَ ]

صدق الله العظيم

النمل. اية رقم 19



First of all I wish to express my thanks to **ALLAH**, to the Most Merciful and the Most Grateful for His generous care throughout my life.

I cannot find enough words to express my deep feelings towards my supervisors for their great helps and guidance in producing this thesis.

My gratitude and deep appreciation to **Professor**/ **Manal Abd Elalim Abd Elsattar**, Professor of Clinical and Chemical Pathology,
Faculty of Medicine – Ain Shams University for her guidance, valuable
advice, continuous encouragement and close supervision. I have the honor to
complete this work under her supervision.

I would also to extend my thanks and gratitude to **Professor**/ **Mohamed Abd Elmaboud Mohamed**, Professor of Internal
Medicine, Faculty of Medicine – Ain Shams University, for his great
efforts and help during the whole work; no wards can express my deep
gratefulness.

I am deeply grateful to **Doctor/ Hala Badr El Din Ali Othman**, Assistant Professor of Clinical and Chemical Pathology,
Faculty of Medicine – Ain Shams University for her great help and encouragement during this work.

I would like to express my sincere thanks and highest appreciation to **Doctor/ Hala Mahmoud Hafez**, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine – Ain Shams University, for her support, wise advice and precious time she had offered me.

Lastly I would like to express my thanks to everyone in the Medical Reasearch Centre who helped me during work and my deep thanks to Doctor Mohammed Sharaf Eldeen (lecturer) of Molucular Biology, Medical Research Centre, Ain Shams University, for his great help during this work.



## **List of Contents**

| Subject   | Page No |
|---|---------|
| List of Abbreviations                             | i       |
| List of Tables                                    | ii      |
| List of Figures                                   | iii     |
| Abstract  |         |
| Introduction                                      | 1       |
| Aim of the Work                                   | 4       |
| <b>Review of Literature</b>                       |         |
| Helicobacter                                      | 5       |
| Helicobacter Species and Liver Diseases           | 29      |
| Diagnosis of Helicobacter Species in Liver Diseas | e36     |
| Treatment of Helicobacter infection               | 59      |
| Prevention and vaccination                        | 62      |
| Patients and Methods                              | 64      |
| Results   | 80      |
| Discussion  | 92      |
| Conclusion  | 101     |
| Recommendations                                   | 102     |
| Summary   | 101     |
| References  | 106     |
| Arabic Summary                                    |         |

### **List of Abbreviations**

**AFP** : Alpha fetoprotein

**Cdt** : Cytolethal Distending Toxin

**CLO** : Campylobacter-like organism test

**CLSI** : Clinical and laboratory standard institute

**CPI** : Cag Pathogenicity Island

**EGF** : Epidermal growth factor

**EGFR** : Epidermal Growth Factor Receptor

**EIA** : Enzyme Immuno Assay

**HBV** : Hepatitis B virus

**HCV** : Hepatitis C virus

**HCC**: Hepatocellular carcinoma

**HIV** : Human immunodeficiency virus

**INF-**γ : Gamma interferon

**ITP** : Idiopathic thrombocytopenic purpura

**MALT** : Mucosa associated lymphoid tissue

**MIC** : Minimal inhibitory concentration

**MMP** : Matrix Metallo Proteinases

**PCR** : Polymerase Chain reaction

**PUD** : Peptic ulcer disease

**RFLP**: Restriction Fragment Length Polymorphism

**RUT** : Rapid urease test

**TK** : Tyrosine Kinase

**UBT** : Urea breath test

## **List of Tables**

| Eable No.          | Eitle  | Page No. |
|--------------------|--|----------|
| <b>Table (1):</b>  | Habitats and phenotypic characteristi<br>Helicobacter species (a)  |          |
| <b>Table (2):</b>  | Virulence factors identified in Helicol species  |          |
| <b>Table (3):</b>  | Genes involved by point mutation or genetic events leading to antibiotic resistint <i>Helicobacter</i> . | stance   |
| <b>Table (4):</b>  | The grade of activity in H&E sections:   | 65       |
| <b>Table (5):</b>  | Components of PCR mixture in a volume of 50 $\mu L$  |          |
| <b>Table (6):</b>  | PCR-RFLP pattern of Helicobacter isola   | tes77    |
| <b>Table (7):</b>  | Descriptive data of all patients   | 81       |
| <b>Table (8):</b>  | Data of patients in relation to liver circulativity.   |          |
| <b>Table (9):</b>  | Sex distribution in relation to severi cirrhosis   |          |
| <b>Table (10):</b> | Helicobacter species identified  | 84       |
| <b>Table (11):</b> | Distribution of Helicobacter infection relation to HCV status.   |          |
| <b>Table (12):</b> | Association between Helicobacter info  |          |
| <b>Table (13):</b> | Association between Helicobacter infeand gender  |          |
| <b>Table (14):</b> | Association between Helicobacter infeand HCV infection   |          |
| <b>Table (15):</b> | Distribution of Helicobacter infection severity of liver disease   |          |

## **List of Tables** (Cont.)

| Eable No.          | Citle  | Page No |
|--------------------|--|---------|
| <b>Table (16):</b> | Association between HCV infection severity of cirrhosis                |         |
| <b>Table (17):</b> | Relation between combined infection severity of cirrhosis              |         |
| <b>Table</b> (8):  | Relation between <i>H.pylori</i> infection severity of liver cirrhosis |         |
| <b>Table (19):</b> | Relation between identified Helicologies and severity of cirrhosis     |         |

## **List of Figures**

| Figure No.          | Citle  | Page |  |  |
|---------------------|--|------|--|--|
| Figure (1):         | Spiral shaped bacteria in vicinity of pit cells lineage                            |      |  |  |
| <b>Figure (2):</b>  | Cocci in adjacent hepatocytes by EM  | 12   |  |  |
| <b>Figure (3):</b>  | H.pylori morphology13  |      |  |  |
| <b>Figure (4):</b>  | Morphology of Helicobacters 1  |      |  |  |
| <b>Figure (5):</b>  | Enterohepatic Helicobacter species 1   |      |  |  |
| Figure (6):         | Transmission electron micrographs of Helicobacter sp.                              |      |  |  |
| <b>Figure (7):</b>  | H.pylori gram stain  | 40   |  |  |
| Figure (8):         | H.pylori in gastric biobsy smear after Giemsa staining                             |      |  |  |
| Figure (9):         | H.pylori observed on a gastric biopsy smear after acridine orange staining         |      |  |  |
| <b>Figure (10):</b> | H.heilmanni observed on a gastric biobsy histological preparation (H&E) staining   |      |  |  |
| <b>Figure (11):</b> | Immunohistochemical staining with anti-<br>Helicobacter pylori specific antibodies |      |  |  |
| <b>Figure (12):</b> | Small grey translucent colonies on blood agar media ( <i>H.pylori</i> )            |      |  |  |
| <b>Figure (13):</b> | Helicobacter on blood agar plate   | 47   |  |  |
| <b>Figure (14):</b> | METAVIR Algorithm for Evaluation of Histolgoical Activity                          |      |  |  |
| <b>Figure (15):</b> | Helicobacter infection and liver cirrhosis activity.                               |      |  |  |
| <b>Figure (16):</b> | Association between Helicobacter infection and gender                              |      |  |  |

## List of Figures (Cont.)

| Figure No.          | Citle                             |  |  | Page |
|---------------------|-----------------------------------|--|--|------|
| <b>Figure (17):</b> | Association infection and I       |  |  |      |
| <b>Figure (18):</b> | Distribution of liver cirrhosis a |  |  |      |



## Introduction

repatocellular carcinoma (HCC) was the fourth cause of cancer death worldwide (Moushira et al., 2011). This tumour often follows chronic inflammation and long standing cirrhosis (Pellicano et al., 2004).

Cirrhosis of the liver is a diffuse process, characterized by fibrosis and nodule formation, which stems from hepatocellular injury. The cellular necrosis might originate from viral, toxic, metabolic and autoimmune sources. There are extensive data indicating that chronic infection can lead to cancer in various organs. Parasites such as schistosomes and liver flukes, and a bacterium, Helicobacter pylori, were classified as type I liver carcinogens by the International Agency for Research on Cancer in 1997. The most competing evidence comes from hepatocellular carcinoma (HCC) where chronic hepatitis B virus (HBV) infection is considered to be direct etiological factor and hepatitis C virus (HCV) infection a major risk factor for this disease (Pellicano et al., 2004; Rocha et al., 2005).

Chronic inflammation perse is known to be a factor of progression towards cancer (Cassel, 1998), though HCV itself does not appear to foster a strong inflammatory mechanism. It is thus not yet clear what factor most influence the outcome of the



liver disease. Searching for other noxae has therefore become mandatory (Mosnier et al., 1994).

Helicobacter infections have been implicated in the occurrence of certain liver diseases in some animal species such as Helicobacter canis in dogs, Helicobacter hepaticus Helicobacter bilis in mice. In humans, Helicobacter pylori DNA has been detected in the liver of patients suffering from cholestatic diseases and HCC arising from non cirrhotic liver (Pellicano et al., 2004; Shi et al., 2006).

A study suggested that, presence of Helicobacter species in liver samples could possibly serves as a cofactor in the development of end-stage of liver diseases in humans. These concern have spurred considerable interest in determining the mechanism by which these extracellular bacteria and the associated inflammatory response endorse hepatic and biliary disease (Santosh et al., 2006).

Studies showed a high frequency of *H.pylori* H.pullorum detected by PCR in the liver of patients with cirrhosis and superimposed HCC with and without associated HCV infection, suggesting that, these bacteria might play an important role in the progression of chronic HCV patients to cirrhosis and HCC (Rocha et al., 2005).

The mechanism by which *H. pylori* colonizes the human liver is not totally enlightened. The H. pylori DNA detected in the liver tissue may result from bacterial translocation from the stomach into the blood through the portal system, especially in the later stage of chronic liver disease when portal hypertension occurs. In addition, the bacteria may reach the liver by phagocytes and macrophages or circulating retrograde transfer from the duodenum. Several researchers have suggested that H. pylori may damage hepatocyte by a cytopathic effect (Jose et al., 2014).

## **Aim of the Work**

The aim of the present study is to determine the presence of Helicobacter species in the liver of cirrhotic patients, with or without HCV infection.

## Helicobacter

## **Historical Background:**

Gastric spiral shaped bacteria have been observed in animals and humans for more than 100 years. The first recorded observation of gastric spiral-shaped bacteria in animals was made by Rappin in 1881 and Bizzozero in 1893. The first observation in human was made by Krienitz in 1906 (Fox and Megraud, 2007).

In 1982, Campylobacter pyloridis (later known as Helicobacter pylori) was successfully cultured from stomach biopsy specimens from human patients with gastritis. Subsequently, other spiral gram-negative bacteria have been observed in and isolated from the gastrointestinal tract of mammals such as cats, dogs and rodents (Fox et al., 2000).

### **Taxonomy:**

Initially, many spiral gram-negative bacteria isolated from gastrointestinal tract were grouped Campylobacters. This was based on similar microscopic and ultrastructural morphologies, common microaerobic growth requirements, and similar ecologic niches. However, following extensive analysis of enzymatic activities, fatty acid profiles, 16S rRNA sequence analysis, nucleic acid hybridization and 23S rRNA analysis, the genus Helicobacter was formally distinguished from Campylobacter (Megraud et al., 2012). The Helicobacter belongs class Epsilonproteobacteria, genus to order



campylobacterales, and Helicobacteraceae family, and already involve more than 35 species. Helicobacter Pylori is of primary importance for medicine, however, non-pylori Helicobacter species have been detected in human clinical specimens and showing different organ specificity (Boyanova, 2014).

## **Clinically Significant Helicobacters:**

#### A- Enterohepatic Helicobacter species:

These Helicobacter have been identified in liver specimens from patients with primary sclerosing cholangitis, cholangiocarcinoma, liver cirrhosis, and hepatocellular carcinoma associated with hepatitis C virus infection by genus specific PCR amplification and partial DNA sequencing (Fox and Megraud, 2007). It has been suggested that the presence of these Helicobacter species in liver samples could serve as a co-factor in the development of end stage of liver disease (Pellicano et al., 2008).

#### 1. Helicobacter hepaticus (H.hepaticus):

It was isolated from liver, cecal and colonic mucosa of mice with chronic active hepatitis (*Rocha et al.*, 2005).

*H.hepaticus* known to cause chronic active hepatitis and is associated with multifocal necrotic hepatitis in many strains of mice, and is responsible for the development of hepatic adenoma and hepatocellular carcinoma in mice (Santosh et al., **2006**). This organism has been isolated from human and has